We hope this message finds you well. Prevent Blindness is helping VOZ Advisors, a consulting firm that specializes in patient advocacy and engagement during the drug development process. They are currently working with a global biopharmaceutical company to gain a deeper understanding of the challenges and experiences faced by individuals living with neovascular age-related macular degeneration [Read More]
Category: Latest News
Free Webinar: Therapeutic Targets for Dry AMD
David Boyer, M.D. – Therapeutic Targets for Dry AMD October 3, 2023 at 7:00 p.m. EDT Registration: https://bit.ly/45FfFdB The Foundation Fighting Blindness, the global leader in driving research for treatments and cures for blinding retinal diseases, will host a free webinar on Tuesday, October 3, 2023, from 7:00 – 8:00 p.m. ET. During the [Read More]
IZERVAY™, is the Second Treatment Approved by the FDA for Geographic Atrophy
IZERVAY™ reduced the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials. IZERVAY slowed loss of photoreceptors and disease progression as early as six months. Astellas Pharma Inc. announced on August 5, 2023 that the U.S. Food and Drug Administration (FDA) approved IZERVAY™ (avacincaptad pegol intravitreal solution) for the [Read More]
Free Updated “GuideMe” Book for AMD Now Online
Similar to a practicing low vision therapist, the GuideMe Book for age-related macular degeneration gathers personal information from the client, then offers guidance and resources unique to the client’s personal needs and goals. Prevent Blindness, a patient advocacy organization preserving vision and eye health for more than 115 years, continues to give the gift of [Read More]
Important New Survey Identifies Impact of Blindness and Low Vision on Senior Adults
Big data reports for each U.S state are now available from the survey. VisionServe Alliance and The Ohio State University College of Optometry have completed an important national project to comprehensively describe Americans ages 65 and older who are blind or have low vision. The data sets analyzed are from the CDC’s Behavioral Risk [Read More]